Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury.

IF 6.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
JCI insight Pub Date : 2026-09-17 eCollection Date: 2026-10-22 DOI:10.1172/jci.insight.200429
Bryce C Murillo, Alexander Young, Kaitlyn L Wintruba, Alexander J Eichert, Klara Siejda, Dennon Hoernig, Leigh A Bradley, Bryana N Harris, Catherine Zhao, Michelle Wu, Emmanuel Deau, Mattias F Lindberg, Laurent Meijer, Jeffrey J Saucerman, Matthew J Wolf
{"title":"Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury.","authors":"Bryce C Murillo, Alexander Young, Kaitlyn L Wintruba, Alexander J Eichert, Klara Siejda, Dennon Hoernig, Leigh A Bradley, Bryana N Harris, Catherine Zhao, Michelle Wu, Emmanuel Deau, Mattias F Lindberg, Laurent Meijer, Jeffrey J Saucerman, Matthew J Wolf","doi":"10.1172/jci.insight.200429","DOIUrl":null,"url":null,"abstract":"<p><p>The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle reentry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM reentry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA sequencing data from DYRK1A inhibitor-treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small-molecule inhibitors of DYRK1A is mediated by the induction of cycling CMs.</p>","PeriodicalId":14722,"journal":{"name":"JCI insight","volume":" ","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCI insight","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1172/jci.insight.200429","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/22 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The adult mammalian heart has a limited ability to regenerate lost myocardium following myocardial infarction (MI), largely due to the poor proliferative capacity of cardiomyocytes (CMs). Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a known regulator of cell quiescence, though the mechanisms underlying its function remain unclear. Previous studies have shown that pharmacological inhibition of DYRK1A using harmine induces CM cell cycle reentry after ischemia/reperfusion (I/R) MI. Here, we developed a computational network model of DYRK1A-mediated regulation of the cell cycle, which predicts how DYRK1A inhibition promotes CM reentry. To validate these predictions, we tested selective DYRK1A inhibitors and observed robust induction of cell cycle activity in neonatal rat cardiomyocytes (NRCMs). Integrating our network model with bulk RNA sequencing data from DYRK1A inhibitor-treated NRCMs, we identified E2F1 as a key transcriptional driver of cell cycle gene expression. Finally, we demonstrate that both pharmacological and post-developmental inhibition of DYRK1A enhances heart function and increases CM cycling following I/R MI. Our findings suggest that functional recovery induced by small-molecule inhibitors of DYRK1A is mediated by the induction of cycling CMs.

网络模型预测DYRK1A抑制如何促进缺血/再灌注损伤后的心肌细胞循环。
成年哺乳动物心脏在心肌梗死(MI)后再生失去的心肌的能力有限,主要是由于心肌细胞(CMs)的增殖能力差。双特异性酪氨酸磷酸化调节激酶1A (DYRK1A)是一种已知的细胞静止调节因子,尽管其功能的机制尚不清楚。先前的研究表明,使用毒芹碱对DYRK1A的药理抑制可诱导缺血/再灌注(I/R) MI后CM细胞周期的再进入。在此,我们建立了DYRK1A介导的细胞周期调节的计算网络模型,该模型预测了DYRK1A抑制如何促进CM再进入。为了验证这些预测,我们测试了选择性DYRK1A抑制剂,并在新生大鼠心肌细胞(NRCMs)中观察到细胞周期活性的强大诱导。将我们的网络模型与DYRK1A抑制剂处理的nrcm的大量rna测序数据相结合,我们发现E2F1是细胞周期基因表达的关键转录驱动因子。最后,我们证明了DYRK1A的药理学和发育后抑制都能增强I/R MI后的心脏功能,并增加CM循环。我们的研究结果表明,DYRK1A小分子抑制剂诱导的功能恢复是通过诱导循环CM介导的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JCI insight
JCI insight Medicine-General Medicine
CiteScore
13.70
自引率
1.20%
发文量
543
审稿时长
6 weeks
期刊介绍: JCI Insight is a Gold Open Access journal with a 2022 Impact Factor of 8.0. It publishes high-quality studies in various biomedical specialties, such as autoimmunity, gastroenterology, immunology, metabolism, nephrology, neuroscience, oncology, pulmonology, and vascular biology. The journal focuses on clinically relevant basic and translational research that contributes to the understanding of disease biology and treatment. JCI Insight is self-published by the American Society for Clinical Investigation (ASCI), a nonprofit honor organization of physician-scientists founded in 1908, and it helps fulfill the ASCI's mission to advance medical science through the publication of clinically relevant research reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书